Julio Núñez1,2, Patricia Palau3, Eloy Domínguez3, Anna Mollar1, Eduardo Núñez1, Jose María Ramón1, Gema Miñana1, Enrique Santas1, Lorenzo Fácila4, Jose Luis Górriz5, Juan Sanchis1,2, Antoni Bayés-Genís2,6. 1. Cardiology Department, Hospital Clínico Universitario, INCLIVA, Universitat de València, Valencia, Spain. 2. CIBER Cardiovascular, Madrid, Spain. 3. Cardiology Department, Hospital General Universitario de Castellón, Universitat Jaume I, Castellón, Spain. 4. Cardiology Department, Hospital General Universitario de Valencia, Valencia, Spain. 5. Nephrology Department, Hospital Clínico Universitario, INCLIVA, Universitat de València, Valencia, Spain. 6. Cardiology Service and Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain.
Abstract
BACKGROUND: Sodium-glucose linked transporter 2 inhibition recently emerged as a promising therapy for reducing the risk of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). However, there is a lack of data endorsing its role in symptomatic HF patients. We sought to evaluate the short-term effects of empagliflozin on maximal exercise capacity in these patients. HYPOTHESIS: We postulate tretament with empagliflozin may improve functional capacity in patients with T2DM and established HF. METHODS: Nineteen T2DM patients with symptomatic HF were prospectively included and underwent cardiopulmonary exercise testing before and 30 days after initiation of empagliflozin therapy. A mixed-effects model for repeated measures was used. RESULTS: Median patient age was 72 years (interquartile range, 60-79 years); 42.1% were in New York Heart Association class III. Baseline mean (± SD) peak oxygen consumption (peak VO2 ) was 10.9 ± 4.0 mL/min/kg. Peak VO2 increased significantly at 30 days (∆: +1.21 [0.66 to 1.76] mL/min/kg; P < 0.001). A significant improvement in ventilatory efficiency during exercise, 6-minute walking distance, and quality of life, and a reduction in antigen carbohydrate 125, were also found. Estimated glomerular filtration rate and natriuretic peptides did not significantly change. CONCLUSIONS: In this pilot study, empagliflozin was associated with 1-month improvement in exercise capacity in T2DM patients with symptomatic HF. This beneficial effect was also found for other surrogates of severity.
BACKGROUND: Sodium-glucose linked transporter 2 inhibition recently emerged as a promising therapy for reducing the risk of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). However, there is a lack of data endorsing its role in symptomatic HF patients. We sought to evaluate the short-term effects of empagliflozin on maximal exercise capacity in these patients. HYPOTHESIS: We postulate tretament with empagliflozin may improve functional capacity in patients with T2DM and established HF. METHODS: Nineteen T2DM patients with symptomatic HF were prospectively included and underwent cardiopulmonary exercise testing before and 30 days after initiation of empagliflozin therapy. A mixed-effects model for repeated measures was used. RESULTS: Median patient age was 72 years (interquartile range, 60-79 years); 42.1% were in New York Heart Association class III. Baseline mean (± SD) peak oxygen consumption (peak VO2 ) was 10.9 ± 4.0 mL/min/kg. Peak VO2 increased significantly at 30 days (∆: +1.21 [0.66 to 1.76] mL/min/kg; P < 0.001). A significant improvement in ventilatory efficiency during exercise, 6-minute walking distance, and quality of life, and a reduction in antigen carbohydrate 125, were also found. Estimated glomerular filtration rate and natriuretic peptides did not significantly change. CONCLUSIONS: In this pilot study, empagliflozin was associated with 1-month improvement in exercise capacity in T2DM patients with symptomatic HF. This beneficial effect was also found for other surrogates of severity.
Authors: Marco Guazzi; Ross Arena; Martin Halle; Massimo F Piepoli; Jonathan Myers; Carl J Lavie Journal: Circulation Date: 2016-05-02 Impact factor: 29.690
Authors: Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi Journal: N Engl J Med Date: 2015-09-17 Impact factor: 91.245
Authors: Julio Núñez; Patricia Palau; Eloy Domínguez; Anna Mollar; Eduardo Núñez; Jose María Ramón; Gema Miñana; Enrique Santas; Lorenzo Fácila; Jose Luis Górriz; Juan Sanchis; Antoni Bayés-Genís Journal: Clin Cardiol Date: 2018-04-17 Impact factor: 2.882
Authors: Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman Journal: N Engl J Med Date: 2016-06-14 Impact factor: 91.245
Authors: Julio Núñez; Patricia Palau; Eloy Domínguez; Anna Mollar; Eduardo Núñez; Jose María Ramón; Gema Miñana; Enrique Santas; Lorenzo Fácila; Jose Luis Górriz; Juan Sanchis; Antoni Bayés-Genís Journal: Clin Cardiol Date: 2018-04-17 Impact factor: 2.882
Authors: Moritz J Hundertmark; Olorunsola F Agbaje; Ruth Coleman; Jyothis T George; Rolf Grempler; Rury R Holman; Hanan Lamlum; Jisoo Lee; Joanne E Milton; Heiko G Niessen; Oliver Rider; Christopher T Rodgers; Ladislav Valkovič; Eleanor Wicks; Masliza Mahmod; Stefan Neubauer Journal: ESC Heart Fail Date: 2021-05-06
Authors: Suzanne N Voorrips; Huitzilihuitl Saucedo-Orozco; Pablo I Sánchez-Aguilera; Rudolf A De Boer; Peter Van der Meer; B Daan Westenbrink Journal: Int J Mol Sci Date: 2022-08-03 Impact factor: 6.208
Authors: Devine S Frundi; Eva Kettig; Lena Luise Popp; Melanie Hoffman; Marine Dumartin; Magali Hughes; Edgar Lamy; Yvonne Joko Walburga Fru; Arjola Bano; Taulant Muka; Matthias Wilhelm Journal: Front Cardiovasc Med Date: 2022-07-22
Authors: Salvatore Carbone; Hayley E Billingsley; Justin M Canada; Edoardo Bressi; Brando Rotelli; Dinesh Kadariya; Dave L Dixon; Roshanak Markley; Cory R Trankle; Richard Cooke; Krishnasree Rao; Keyur B Shah; Horacio Medina de Chazal; Juan Guido Chiabrando; Alessandra Vecchié; Megan Dell; Virginia L Mihalick; Roberta Bogaev; Linda Hart; Benjamin W Van Tassell; Ross Arena; Francesco S Celi; Antonio Abbate Journal: Diabetes Metab Res Rev Date: 2020-06-15 Impact factor: 4.876